PT 00114

Drug Profile

PT 00114

Alternative Names: PT 00114

Latest Information Update: 04 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Protagenic Therapeutics
  • Class Antidepressants; Peptides
  • Mechanism of Action Corticotropin-releasing factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anxiety disorders; Depressive disorders; Impulse control disorders; Neurodegenerative disorders

Most Recent Events

  • 28 Apr 2017 Protagenic therapeutics plans to file an IND application with the US FDA in USA for Anxiety and Depression (Protagenic pipeline, April 2017)
  • 28 Apr 2017 Protagenic plans a phase I trial for Anxiety and Depression
  • 18 Apr 2017 Protagenic therapeutics has patent protection for PT 00114 covering teneurin c-terminal associated peptides (TCAP) and methods and uses USA, Australia, Canada and European union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top